Valeant sees FY12 results at top end of forecast
(Reuters) - Canadian drugmaker Valeant Pharmaceuticals International Inc VRX.TO said it expects 2012 results to be at the top end of its previous forecast range.
The company on May 3 raised its 2012 cash earnings forecast by 50 cents per share to a range of $4.45 to $4.70. It expects revenue of $3.4 billion to $3.6 billion in the year.
The company, which has made a string of acquisitions this year, said the forecast does not include recently announced deals such as Natur Produkt International JSC, Acne Free, Swiss Herbal Life Ltd and OraPharma.
Shares of the company closed at C$49.12 on Wednesday on the Toronto Stock Exchange.
(Reporting by Bhaswati Mukhopadhyay in Bangalore; Editing by Sriraj Kalluvila)
© Thomson Reuters 2017 All rights reserved.